Without appropriate monitoring and treatment, up to one in four people living with chronic hepatitis B (CHB) will die from liver failure or liver cancer. Liver cancer, which is largely attributable to viral hepatitis, is the fastest increasing cause of cancer death in Australia. It is estimated that 14,600 people in South Australia have CHB but half of these are undiagnosed. Treatment for hepatitis B can reduce the risk of liver cancer by over 50% in a few years, however only 3% of people in South Australia are currently receiving antiviral treatment.

Successful completion of the training and assessment will accredit community-based medical practitioners to prescribe s100 highly specialised drugs for the treatment of CHB.

Through online learning and interactive face-face teaching, participants will learn to:

- Screen at-risk patients, accurately diagnose CHB infection and assess phase of the disease
- Monitor patients appropriately, establish suitability for treatment and refer to specialist care if indicated
- Discuss aims of treatment, antiviral treatment options, duration of therapy and definitions of response
- Monitor patients on treatment according to established protocols, recognise and manage resistance, hepatitis flares and response
- Recognise risk factors, clinical signs, symptoms and complications of advanced liver disease and manage or refer to specialist care appropriately

This course may be of particular interest to GPs working with patients with barriers to access to specialist services, or those providing services to communities with higher HBV prevalence such as:
- People born in countries of high prevalence
- Aboriginal People
- Prisoners

Register at: [www.ashm.org.au/courses](http://www.ashm.org.au/courses)

Registrations close: Monday, 22 February 2016

For further details contact:
T 02 8204 0740
E education@ashm.org.au

This course is approved for 40 Category 1 RACGP QI&CPD points.

ASHM is an authorised provider of accredited activities under the RACGP QI&CPD Program.